Crossref
New treatment options for crizotinib-resistant ALK-positive non-small cell lung cancer patients
AME Clinical Trials Review · 2024
DOI: 10.21037/actr-23-28 ↗Kurz gefasst
Fachartikel in der Zeitschrift AME Clinical Trials Review, 2024. Verfasst von Akikazu Kawase.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Kawase, A. (2024). New treatment options for crizotinib-resistant ALK-positive non-small cell lung cancer patients. AME Clinical Trials Review. https://doi.org/10.21037/actr-23-28
Vancouver
Kawase A. New treatment options for crizotinib-resistant ALK-positive non-small cell lung cancer patients. AME Clinical Trials Review. 2024. doi:10.21037/actr-23-28
BibTeX
@article{Kawase2024,
author = {Kawase, Akikazu},
title = {New treatment options for crizotinib-resistant ALK-positive non-small cell lung cancer patients},
journal = {AME Clinical Trials Review},
year = {2024},
doi = {10.21037/actr-23-28}
}
EUVIMED